Research On Financial Performance Evaluation Of Harbin Pharmaceutical Group Co.,Ltd Based On EVA

In 2017,it was the year in which many important policies of the pharmaceutical industry were implemented,and it was a year in which the reform of the pharmaceutical industry was further advanced.Although affected by policies such as drug bidding,medical insurance control fees,and medical insurance catalogue adjustments,some drug prices continued to decline,and the income and profit growth rate of related pharmaceutical companies slowed down compared with the previous period,but with the growth of medical insurance coverage,per capita medical consumption growth,and population.The impact of aging and industrial technology innovation will continue to promote the rapid development of China's pharmaceutical industry.The results of financial performance evaluation directly reflect the value of enterprises and the potential of development.They are an important basis for investors' decision-making and a basis for measuring business performance.This thesis takes Harbin Pharmaceutical Group Co.,Ltd.as the research object,expounds the research status of domestic and foreign scholars on financial performance and economic value added,and expounds the general situation and financial status of Harbin Pharmaceutical Group.Compared with the traditional financial performance evaluation centered on profit assessment,EVA considers the impact of the total capital cost of the enterprise,that is,the cost of debt capital and the cost of equity capital on the evaluation of financial performance.The necessity of introducing EVA and the reasons for its introduction Kind of influence.At the same time,a series of project adjustments are made to the profit of accounting,and the value of accounting profit is calculated based on the principle of stability,which avoids the impact of accounting treatment on the final result,and truly reflects the situation of the enterprise and reduces the error.Based on the actual situation of Harbin Pharmaceutical Group,the EVA financial performance evaluation index system was established based on the characteristics of the group.Using the report data of Harbin Pharmaceutical Group,the analytic hierarchy process and the efficacy coefficient method were used to comprehensively evaluate the financial performance of Harbin Pharmaceutical Group and evaluate the results.The analysis,combined with Harbin Pharmaceutical Group's actual and factors affecting financial performance,proposes strategies to improve its financial performance.The research in this thesis is of great significance for improving the financial performance level of Harbin Pharmaceutical Group,promoting the healthy development of Harbin Pharmaceutical Group,and providing reference for other pharmaceutical manufacturing enterprises.